Xencor (XNCR)
(Delayed Data from NSDQ)
$24.29 USD
-0.28 (-1.14%)
Updated Dec 24, 2024 01:00 PM ET
After-Market: $24.25 -0.04 (-0.16%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
XNCR 24.29 -0.28(-1.14%)
Will XNCR be a Portfolio Killer in December?
Zacks Investment Research is releasing its prediction for XNCR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for XNCR
All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy
Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet
XNCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross
Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates
Other News for XNCR
Xencor’s Promising Pipeline and Strategic Partnerships Drive Buy Rating
Xencor initiated with an Overweight at Wells Fargo
Xencor initiated with bullish view at Wells Fargo, here's why
Promising Prospects for Xencor’s Plamotamab in Autoimmune Treatments Drive Buy Rating
Critical Insights From Xencor Analyst Ratings: What You Need To Know